Eovist^® is indicated for intravenous use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in patients with known or suspected focal liver disease.

In addition to dynamic-phase imaging, Eovist^® specifically targets functioning hepatocytes within the liver providing additional morphological and functional images about lesion cell composition.^1,2

How Eovist^®, a hepatobiliary agent, works²

• Following Injection, Eovist^® is equally eliminated through the renal and hepatic systems
• Eovist^® is initially distributed in the extracellular space, allowing for arterial, portal venous, and transitional imaging phase^1,3
• Further assessment of lesions through hepatobiliary phase imaging at 20 minutes post injection:
  •  Lesions with little or no hepatobiliary function will generally not accumulate Eovist^® 
  • Lesions with normal hepatobiliary function will accumulate Eovist^®

References: 1. Eovist^® [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2018. 2. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics. 2009;29:1725-1748. doi: 10.1148/rg.296095515. 3. American College of Radiology CT/MRI Li-RADS 2018 CORE.

In clinical trials among 1,989 patients, of whom 1,581 received the recommended dose:

• Overall, 4% of subjects reported one or more reactions during a follow-up period that for most subjects extended 24 hours after Eovist^® administration. The adverse reactions were predominantly of mild to moderate severity.
• The most frequent (≥0.5%) adverse reactions associated with the use of Eovist^® were nausea, headache, feeling hot, dizziness, and back pain.

Dosing Eovist^®

• Due to high relaxivity in plasma and the liver, the approved dose of Eovist^® injection is 0.025 mmol/kg.¹

The Eovist^® 15 mL single-dose vial is available to conveniently dose patients weighing 220 lbs to 330 lbs.

• Quality: Maintain image quality through appropriate weight-based dosing in patients requiring >10 mL
• Minimization of waste: Use one 15 mL vial instead of two 10 mL vials

Dynamic and functional liver imaging in <30 minutes¹

Eovist^® MRIs don’t have to require extended table time. Imaging protocols with Eovist^® allow for the collection of dynamic and functional information in under 30 minutes¹, that is important to your department and patient scheduling needs.

References: 1. Eovist^® [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2018. 2. American College of Radiology CT/MRI Li-RADS 2018 CORE. 3. Jhaveri K, Cleary S, Pascale A. Consensus Statements From a Multidisciplinary Expert Panel on the Utilization and Application of a Liver-Specific MRI Contrast Agent (Gadoxetic Acid). Am J Roentgen AJR. 2015;204:498-509. 4. Yoshioka H, Takahashi N, Yamaguchi M. Double Arterial Phase Dynamic MRI with Sensitivity Encoding (SENSE) for Hypervascular Hepatocellular Carcinomas. J Magn Reson Imaging. 2002;16:259-266.

See Eovist in action with the case studies below. Or go to the Resources section to see all videos.

Eovist^® Packaging

•  Eovist^® injection is supplied in single-dose, rubber-stoppered vials containing 181.43 mg/mL of gadoxetate disodium, equivalent to 0.25 mmol/mL
• The recommended dose of Eovist^® injection is 0.025 mmol/kg body weight